Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On September 2, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global license and collaboration agreement with Novartis for ARO-SNCA, the preclinical siRNA therapy targeting alpha-synuclein for the treatment of various synucleinopathies (e.g., Parkinson's Disease), along with additional collaboration targets that will utilize Arrowhead's TRiM platform.</li><li>Arrowhead will receive an upfront payment of $200 million and is eligible to receive up to $2 billion in potential milestone payments plus royalties on commercial sales.</li><li> In addition, on September 3, 2025, Ionis Pharmaceuticals, Inc. (IONS) announced positive topline results from the Phase 3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyceridemia (sHTG), in which reductions of fasting triglycerides of up to 72% and an 85% reduction in acute pancreatitis events were seen.</li></ul>

On September 2, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced a global license and collaboration agreement with Novartis for ARO-SNCA, the preclinical siRNA therapy targeting alpha-synuclein for the treatment of various synucleinopathies (e.g., Parkinson's Disease), along with additional collaboration targets that will utilize Arrowhead's TRiM platform.Arrowhead will receive an upfront payment of $200 million and is eligible to receive up to $2 billion in potential milestone payments plus royalties on commercial sales. In addition, on September 3, 2025, Ionis Pharmaceuticals, Inc. (IONS) announced positive topline results from the Phase 3 CORE and CORE2 studies of olezarsen in patients with severe hypertriglyceridemia (sHTG), in which reductions of fasting triglycerides of up to 72% and an 85% reduction in acute pancreatitis events were seen.

ARWR: Signs Collaboration Agreement with Novartis with 200 Million Upfront 